Clayman GL: The current status of gene therapy. Semin Oncol. 2000, 27: 39-43.
CAS
PubMed
Google Scholar
Gibson SA, Pellenz C, Hutchison RE, Davey F, Shillitoe EJ: Induction of apoptosis in oral cancer cells by an anti-bcl-2 ribozyme delivered by an adenovirus vector. Clin Cancer Res. 2000, 6: 213-222.
CAS
PubMed
Google Scholar
Shillitoe EJ: Papillomaviruses as targets for cancer gene therapy. Cancer Gene Ther. 2006, 13: 445-450. 10.1038/sj.cgt.7700926.
Article
CAS
PubMed
Google Scholar
He Y, Zeng Q, Drenning SD, Melhem MF, Tweardy DJ, Huang L, et al: Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter. J Natl Cancer Inst. 1998, 90: 1080-1087. 10.1093/jnci/90.14.1080.
Article
CAS
PubMed
Google Scholar
Xi S, Grandis JR: Gene therapy for the treatment of oral squamous cell carcinoma. J Dent Res. 2003, 82: 11-16. 10.1177/154405910308200104.
Article
CAS
PubMed
Google Scholar
Shillitoe EJ, Hermonat PL, Noonan S, Shi B: Effectiveness of different promoters in adeno-associated virus vectors for expression of genes in oral cancer cells. Int J Oral Biol. 2001, 26: 7-14.
Google Scholar
Tyminski E, Leroy S, Terada K, Finkelstein DM, Hyatt JL, Danks MK, et al: Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan. Cancer Res. 2005, 65: 6850-6857. 10.1158/0008-5472.CAN-05-0154.
Article
CAS
PubMed
Google Scholar
Omalley BW, Cope KA, Chen SH, Li D, Schwarta MR, Woo SL: Combination gene therapy for oral cancer in a murine model. Cancer Res. 1996, 56: 1737-1741.
CAS
Google Scholar
Clayman GL, Trapnell BC, Mittereder N, Liu TJ, Eicher S, Zhang S, et al: Transduction of normal and malignant oral epithelium by an adenovirus vector: the effect of dose and treatment time on transduction efficiency and tissue penetration. Cancer Gene Ther. 1995, 2: 105-111.
CAS
PubMed
Google Scholar
Sauthoff H, Hu J, Maca C, Goldman M, Heitner S, Yee H, et al: Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: virus persists and spreads systemically at late time points. Human Gene Ther. 2003, 14: 425-433. 10.1089/104303403321467199.
Article
CAS
Google Scholar
Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL: Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nature Med. 1995, 1: 938-943. 10.1038/nm0995-938.
Article
CAS
PubMed
Google Scholar
Bennett J, Delman K, Burt B, Mariotti A, Malhotra S, Zager J, et al: Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer. Cancer Gene Ther. 2002, 9: 935-945. 10.1038/sj.cgt.7700510.
Article
CAS
PubMed
Google Scholar
Meignier B, Martin B, Whitley R, Roizman B: In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J Infect Dis. 1990, 162: 313-321.
Article
CAS
PubMed
Google Scholar
Wong RJ, Patel SG, Kim SH, DeMatteo RP, Malhotra S, Bennett JJ, et al: Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma. Hum Gene Ther. 2001, 12: 253-265. 10.1089/10430340150218396.
Article
CAS
PubMed
Google Scholar
Carew JF, Kooby DA, Halterman MW, Federoff HJ, Fong Y: Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus Type-1 (G207). Hum Gene Ther. 1999, 10: 1599-1606. 10.1089/10430349950017608.
Article
CAS
PubMed
Google Scholar
Kirn D: Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer; what have we learned?. Gene Ther. 2001, 8: 89-98. 10.1038/sj.gt.3301377.
Article
CAS
PubMed
Google Scholar
Crompton AM, Kirn DH: From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development. Curr Cancer Drug Targets. 2007, 7: 133-139. 10.2174/156800907780058862.
Article
CAS
PubMed
Google Scholar
Miyatake S, Iyer A, Martuza RL, Rabkin SD: Transcriptional targeting of herpes simplex virus for cell-specific replication. J Virol. 1997, 71: 5124-5132.
PubMed Central
CAS
PubMed
Google Scholar
Yamamura H, Hashio M, Noguchi M, Sugenoya Y, Asakada M, Hirano N, et al: Identification of the transcriptional regulatory sequences of human calponin promoter and their use in targeting a conditionally replicating herpes vector to malignant human soft tissue and bone tumors. Cancer Res. 2001, 61: 3969-3977.
CAS
PubMed
Google Scholar
Chung RY, Saeki Y, Chiocca EA: B-myb promoter retargeting of herpes simplex virus gamma-34.5 gene-mediated virulence toward tumor and cycling cells. J Virol. 1999, 73: 7556-7564.
PubMed Central
CAS
PubMed
Google Scholar
Kasuya H, Pawlik T, Mullen J, Donahue J, Nakamura H, Chandrasekhar S, et al: Selectivity of an oncolytic herpes simplex virus for cells expressing the DF3/MUC1 antigen. Cancer Res. 2004, 64: 2561-2567. 10.1158/0008-5472.CAN-03-3431.
Article
CAS
PubMed
Google Scholar
Shillitoe EJ, Noonan S: Strength and specificity of different gene promoters in oral cancer cells. Oral Oncol. 2000, 36: 214-220. 10.1016/S1368-8375(99)00064-0.
Article
CAS
PubMed
Google Scholar
Griffith C, Noonan S, Lou E, Shillitoe EJ: An oncolytic mutant of herpes simplex virus type-1 in which replication is governed by a promoter/enhancer of human papillomavirus type-16. Cancer Gene Ther. 2007, 14: 985-993. 10.1038/sj.cgt.7701089.
Article
CAS
PubMed
Google Scholar
Teichler Zallen D: US gene therapy in crisis. Trends Genet. 2000, 16: 272-275. 10.1016/S0168-9525(00)02025-4.
Article
CAS
PubMed
Google Scholar
Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, Morillon E, et al: Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest. 2008, 118: 3132-3142. 10.1172/JCI35700.
Article
PubMed Central
CAS
PubMed
Google Scholar
Toda M, Martuza RL, Rabkin SD: Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor. Mol Ther. 2000, 2: 324-329. 10.1006/mthe.2000.0130.
Article
CAS
PubMed
Google Scholar
Israyelyan AH, Melancon JM, Lomax LG, Sehgal I, Lauschner C, Kearney MT, et al: Effective treatment of human breast tumor in a mouse xenograft model with herpes simplex virus type 1 specifying the NV1020 genomic deletion and the gBsyn3 syncytial mutation enabling high viral replication and spread in breast cancer cells. Hum Gene Ther. 2007, 18: 457-473. 10.1089/hum.2006.145.
Article
CAS
PubMed
Google Scholar
Ikeda K, Ichikawa T, Wakimoto H, Silver JS, Deisboeck TS, Finkelstein D, et al: Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nature Med. 1999, 5: 881-887. 10.1038/11320.
Article
CAS
PubMed
Google Scholar
Ikeda K, Wakimoto H, Ichikawa T, Jhung S, Hochberg FH, Louis DN, et al: Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J Virol. 2000, 74: 4765-4775. 10.1128/JVI.74.10.4765-4775.2000.
Article
PubMed Central
CAS
PubMed
Google Scholar
Fulci G, Breymann L, Gianni D, Kurozomi K, Rhee SS, Yu J, et al: Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. PNAS (USA). 2006, 103: 12873-12878. 10.1073/pnas.0605496103.
Article
CAS
Google Scholar
Miller CG, Fraser NW: Role of the immune response during neuro-attenuated herpes simplex virus-mediated tumor destruction in a murine intracranial melanoma model. Cancer Res. 2000, 60: 5714-5722.
CAS
PubMed
Google Scholar
Shillitoe EJ, Pellenz C: Factors that limit the effectiveness of herpes simplex virus type 1 for treatment of oral cancer in mice. Clin Cancer Res. 2005, 11: 3109-3116. 10.1158/1078-0432.CCR-04-2302.
Article
CAS
PubMed
Google Scholar
Kuriyama N, Kuriyama H, Julin CM, Lamborn KR, Israel MA: Protease pretreatment increases the efficacy of adenovirus-mediated gene therapy for the treatment of an experimental glioblastoma model. Cancer Res. 2001, 61: 1805-1809.
CAS
PubMed
Google Scholar
Ganesh S, Gonzalez-Edick M, Gibbons D, Van Roey M, Joos K: Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models. Clin Cancer Res. 2008, 14: 3933-3941. 10.1158/1078-0432.CCR-07-4732.
Article
CAS
PubMed
Google Scholar
McKee TD, Grandi P, Mok W, Alexandrakis G, Insin N, Zimmer JP, et al: Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res. 2006, 66: 2509-2513. 10.1158/0008-5472.CAN-05-2242.
Article
CAS
PubMed
Google Scholar
Ganesh S, Gonzalez Edick M, Idamakanti N, Abramova M, Vanroey M, Robinson M, et al: Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice. Cancer Res. 2007, 67: 4399-4407. 10.1158/0008-5472.CAN-06-4260.
Article
CAS
PubMed
Google Scholar
Nagano S, Perentes JY, Jain RK, Boucher Y: Cancer cell death enhances the penetration and efficacy of oncolytic herpes simplex virus in tumors. Cancer Res. 2008, 68: 3795-3802. 10.1158/0008-5472.CAN-07-6193.
Article
PubMed Central
CAS
PubMed
Google Scholar
Chahlavi A, Todo T, Martuza RL, Rabkin SD: Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia. 1999, 1: 162-169. 10.1038/sj.neo.7900016.
Article
PubMed Central
CAS
PubMed
Google Scholar
Cinatl J, Cinatl J, Michaelis M, Kabickova H, Kotchetkav R, Vogel JU, et al: Potent oncolytic activity of multimutated herpes simplex virus G207 in combination with vincristine against human rhabdomyosarcoma. Cancer Res. 2003, 63: 1508-1514.
CAS
PubMed
Google Scholar
Eisenberg DP, Adsumilli PS, Hendershott KJ, Yu Z, Mullerad M, Chan MK, et al: 5-Fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer. J Gastrointest Surg. 2005, 9: 1068-1079. 10.1016/j.gassur.2005.06.024.
Article
PubMed Central
PubMed
Google Scholar
Katsura T, Iwai S, Ota Y, Shimizu H, Ikuta K, Yura Y: The effects of trichostatin A on the oncolytic ability of herpes simplex virus for oral squamous cell carcinoma cells. Cancer Gene Ther. 2008, advance online publication
Google Scholar
Lou E, Kellman RM, Shillitoe EJ: Effect of herpes simplex virus type-1 on growth of oral cancer in an immunocompetent, orthotopic mouse model. Oral Oncol. 2002, 38: 349-356. 10.1016/S1368-8375(01)00069-0.
Article
CAS
PubMed
Google Scholar
Naito S, Obayashi S, Sumi T, Iwai S, Nakazawa M, Ikuta K, et al: Enhancement of antitumor activity of herpes simplex virus gamma(1)34.5-deficient mutant for oral squamous cell carcinoma cells by hexamethylene bisacetamide. Cancer Gene Ther. 2006, 13: 780-791. 10.1038/sj.cgt.7700957.
Article
CAS
PubMed
Google Scholar
Stanziale SF, Petrowsky H, Adusumilli PS, Ben-Porat L, Gonen M, Fong Y: Infection with oncolytic herpes simplex virus-1 induces apoptosis in neighboring human cancer cells: a potential target to increase anticancer activity. Clin Cancer Res. 2004, 10: 3225-3232. 10.1158/1078-0432.CCR-1083-3.
Article
CAS
PubMed
Google Scholar
Stiles BM, Adusumilli PS, Stanziale SF, Eisenberg DP, Bhargava A, Kim TH, et al: Estrogen enhances efficacy of an oncolytic HSV-1 mutant in the treatment of estrogen receptor positive breast cancer. Int J Oncol. 2006, 28: 1429-1439.
PubMed Central
CAS
PubMed
Google Scholar
Bennett JJ, Adsumilli P, Petrowsky H, Burt BM, Roberts G, Delman KA, et al: Up-regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a gamma134.5 deleted oncolytic herpes virus (G207). FASEB J. 2004, 18: 1001-1003.
CAS
PubMed
Google Scholar
Ganesh S, Gonzalez-Edick M, Gibbons D, Ge Y, Vanroey M, Robinson M, et al: Combination therapy with radiation or cisplatin enhances the potency of Ad5/35 chimeric oncolytic adenovirus in a preclinical model of head and neck cancer. Cancer Gene Ther. 2008,
Google Scholar
Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, et al: A controlled trial of intratumoral ONYX-015, a selectively replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nature Med. 2000, 6: 879-885. 10.1038/78638.
Article
CAS
PubMed
Google Scholar
Aghi M, Rabkin S, Martuza RL: Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. J Natl Cancer Inst. 2006, 98: 38-50.
Article
CAS
PubMed
Google Scholar